American Pharmaceutical Review publishes an article by John H. Stone, MD MPH, Chair of the Steritas Scientific Advisory Board. You can read the article here. Full reference: American Pharmaceutical ...
John Stone, MD MPH, Chair of Steritas Scientific Board, discusses the true cost of steroid-toxicity with Drug Discovery & Development (DD&D). Read the full article here.
Steritas' John Stone analyses the benefits that a quantifiable index system can have for researchers looking into steroid toxicity, and how this can allow them to work with larger sets of patient ...
The Journal for Clinical Studies (JCS) sat down with John Stone, MD MPH, Chair of the Steritas Scientific Board, to discuss the steroid-toxicity epidemic. Read the full interview here.
Megan Thomas of Drug Discovery World (DDW) spoke with Martha Stone, CEO of Steritas, and other industry experts about their predictions for drug discovery opportunities in 2025. Read the article here.
First-in-class steroid-toxicity outcome assessments licensed by argenx to support the development of novel steroid-sparing therapeutics for autoimmune diseases Boston, MA, USA, 19 November 2024: ...